CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 95 enrolled
Drug / intervention
ethanol +1 moredrug
Likely dose
70% ethanol catheter lock therapy, dose and frequency not specified in protocolAI-extracted
Key inclusion· 5
  • Age 6 months to <25 years and weight ≥5 kg
  • New diagnosis of CLABSI within 96 hours of first positive blood culture; prior CLABSI permitted if not previously enrolled
  • Silicone central venous access device in place (ports, Hickman, or Broviac lines)
  • Clinician plans to attempt salvage of the CVAD
Key exclusion· 9
  • Allergy to ethanol or placebo lock components
  • Concomitant use of metronidazole, disulfiram, or trabectedin
  • Plan to remove CVAD within 6 days
  • All lumens of CVAD in continuous use preventing ≥2 hours daily lock per lumen

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01472965
NCT01472965Phase 3Completed

A Double-Blind, Randomized, Placebo-Controlled, Trial of Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line Associated Bloodstream Infection (CLABSI) in Children and Adolescents

St. Jude Children's Research Hospital·interventional·Posted Nov 17, 2011·Updated Nov 13, 2017

In Brief

A Phase 3 clinical trial evaluating ethanol and heparin-saline placebo for Central Line-Associated Bloodstream Infection. Completed, enrolled 95 participants across 2 sites in 2 countries.

Detailed Summary

Use of long-term central venous access devices (including tunneled lines and ports) can be associated with development of bloodstream infection caused by build-up of bacteria or fungus on the inside of the device, called central line associated bloodstream infection (CLABSI). This infection generally requires hospital admission and antibiotic therapy. This treatment usually helps eradicate the infection but sometimes it is not possible to clear or it comes back after treatment. Also, once someone has had one line infection the chance of getting another one is higher. This study will test whether treatment and secondary prophylaxis of CLABSI with ethanol lock therapy (ELT) can significantly reduce the risk of treatment failure (comprising failure to clear initial infection, relapse or reinfection) in children and adolescents treated for cancer or hematologic disorders or undergoing hematopoietic stem cell transplantation (HSCT). ELT involves injecting a solution of ethanol and water into the line or port, allowing it to dwell for 2 hours, and then withdrawing the solution.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 17, 2011
Enrollment StartDec 29, 2011
Primary CompletionNov 11, 2016
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 14.6 years ago

Interventions

ethanoldrug

70% ethanol catheter lock therapy

heparin-saline placebodrug

heparin-saline placebo catheter lock therapy